NCT05675761

The Efficacy and Safety of Azovudine in the Treatment of COVID-19

A Prospective, Multicenter, Real World Study to Evaluate the Efficacy and Safety of Azovudine in the Treatment of COVID-19

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multicenter clinical study. It is intended to discuss the efficacy of starting Azovudine treatment as early as possible for all types of patients of COVID-19, the time of remission of specific symptoms, the proportion of patients with severe diseases, oxygen and conditions, and related adverse reactions, so as to understand the efficacy and safety of Azovudine treatment in all types of COVID-19, and provide real world data support for the treatment of the majority of COVID-19 patients.

Detailed description

1. To evaluate the clinical efficacy of Azovudine in the treatment of mild, moderate and severe COVID-19. 2. To explore the safety and adverse reactions of Azovudine in the whole population of COVID-19. 3. To explore the remission time of clinical symptoms, signs and images of patients with COVID-19 treated with Azovudine. 4. Explore the clinical guiding value of CORMB score.

Conditions

• COVID-19
• Infections
• Morality
• Death, Assisted

Interventions

Type	Name	Description
DRUG	Azorubine	Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)

Timeline

• Start date: 2023-01-04
• Primary completion: 2024-10-31
• Completion: 2024-10-31
• First posted: 2023-01-09
• Last updated: 2023-01-10

Locations

1 site across 1 country: China